|
1.
|
Brooks SA, Lomax-Browne HJ, Carter TM,
Kinch CE and Hall DM: Molecular interactions in cancer cell
metastasis. Acta Histochem. 112:3–25. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Bahr C and Groner B: The IGF-1 receptor
and its contributions to metastatic tumor growth-novel approaches
to the inhibition of IGF-1R function. Growth Factors. 23:1–14.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Wu H, Reynolds AB, Kanner SB, Vines RR and
Parsons JT: Identification and characterization of a novel
cytoskeleton-associated pp60src substrate. Mol Cell Biol.
11:5113–5124. 1991.PubMed/NCBI
|
|
4.
|
Wu H and Parsons JT: Cortactin, an
80/85-kilodalton pp60src substrate, is a filamentous actin-binding
protein enriched in the cell cortex. J Cell Biol. 120:1417–1426.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Weed SA and Parsons JT: Cortactin:
coupling membrane dynamics to cortical actin assembly. Oncogene.
20:6418–6434. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Daly RJ: Cortactin signalling and dynamic
actin networks. Biochem J. 382:13–25. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Schuuring E, Verhoeven E, Litvinov S and
Michalides RJ: The product of the EMS1 gene, amplified and
overexpressed in human carcinoma, is homologous to a v-src
substrate and is located in cell-substratum contact sites. Mol Cell
Biol. 13:2891–2898. 1993.PubMed/NCBI
|
|
8.
|
Ormandy CJ, Musgrove EA, Hui R, Daly RJ
and Sutherland RL: Cyclin D1, EMS1 and 11q13 amplification in
breast cancer. Breast Cancer Res Treat. 78:323–335. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Head JA, Jiang D, Li M, Zorn LJ, Schaefer
EM, Parsons JT and Weed SA: Cortactin tyrosine phosphorylation
requires Rac1 activity and association with the cortical actin
cytoskeleton. Mol Biol Cell. 14:3216–3229. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Rosenzweig SA and Atreya HS: Defining the
pathway to insulin-like growth factor system targeting in cancer.
Biochem Pharmacol. 80:1115–1124. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Surmacz E: Function of the IGF-I receptor
in breast cancer. J Mammary Gland Biol Neoplasia. 5:95–105. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Baserga R: The IGF-I receptor in cancer
research. Exp Cell Res. 253:1–6. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Jackson JG, White MF and Yee D: Insulin
receptor substrate-1 is the predominant signaling molecule
activated by insulin-like growth factor I, insulin, and
interleukin-4 in estrogen receptor-positive human breast cancer
cells. J Biol Chem. 273:9994–10003. 1998. View Article : Google Scholar
|
|
14.
|
Schnarr B, Strunz K, Ohsam J, Benner A,
Wacker J and Mayer D: Downregulation of insulin-like growth
factor-I receptor and insulin receptor substrate-1 expression in
advanced human breast cancer. Int J Cancer. 89:506–513. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Peyrat JP, Bonneterre J, Dusanter-Fourt I,
Leroy-Martin B, Dijane J and Demaille A: Characterization of
insulin-like growth factor 1 receptors (IGF-IR) in human breast
cancer cell lines. Bull Cancer. 76:311–309. 1989.PubMed/NCBI
|
|
16.
|
Sepp-Lorenzino L, Rosen N and Lebwohl DE:
Insulin and insulin-like growth factor signaling are defective in
the MDA-MB-468 human breast cancer cell line. Cell Growth Differ.
5:1077–1083. 1994.PubMed/NCBI
|
|
17.
|
Jackson JG and Yee D: IRS-1 expression and
activation are not sufficient to activate downstream pathways and
enable IGF-I growth response in estrogen receptor negative breast
cancer cells. Growth Horm IGF Res. 9:280–289. 1999. View Article : Google Scholar
|
|
18.
|
Godden J, Leake R and Kerr DJ: The
response of breast cancer cells to steroid and peptide growth
factors. Anticancer Res. 12:1683–1688. 1992.PubMed/NCBI
|
|
19.
|
Dunn SE, Ehrlich M, Sharp NJ, Reiss K,
Solomon G, Hawkins R, Baserga R and Barrett JC: A dominant negative
mutant of the insulin-like growth factor-I receptor inhibits the
adhesion, invasion and metastasis of breast cancer. Cancer Res.
58:3353–3361. 1998.PubMed/NCBI
|
|
20.
|
Arteaga CL, Kitten LJ, Coronado EB, Jacobs
S, Kull FC Jr, Allred DC and Osborne CK: Blockade of the type I
somatomedin receptor inhibits growth of human breast cancer cells
in athymic mice. J Clin Investig. 84:1418–1423. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Doerr ME and Jones Jl: The roles of
integrins and extracellular matrix proteins in the insulin-like
growth factor I-stimulated chemotaxis of human breast cancer cells.
J Biol Chem. 271:2443–2447. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Schlessinger J: Cell signaling by receptor
tyrosine kinases. Cell. 103:211–225. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Arteaga CL: Epidermal growth factor
receptor dependence in human tumors: more than just expression?
Oncologist. 4:31–39. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Davidson NE, Gelmann EP, Lippman ME and
Dickson RB: Epidermal growth factor receptor gene expression in
estrogen receptor-positive and negative human breast cancer cell
lines. Mol Endocrinol. 1:216–223. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Mamot C, Drummond DC, Greiser U, Hong K,
Kirpotin DB, Marks JD and Park JW: Epidermal growth factor receptor
(EGFR)-targeted immunoliposomes mediate specific and efficient drug
delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer
Res. 63:3154–3161. 2003.
|
|
26.
|
Callahan R and Hurvitz S: Human epidermal
growth factor receptor-2-positive breast cancer: current management
of early, advanced, and recurrent disease. Curr Opin Obstet
Gynecol. 23:37–43. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Fillmore CM and Kuperwasser C: Human
breast cancer cell lines contain stem-like cells that self-renew,
give rise to phenotypically diverse progeny and survive
chemotherapy. Breast Cancer Res. 10:R252008. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Charafe-Jauffret E, Ginestier C, Monville
F, Finetti P, Adélaïde J, Cervera N, Fekairi S, Xerri L, Jacquemier
J, Birnbaum D and Bertucci F: Gene expression profiling of breast
cell lines identifies potential new basal markers. Oncogene.
25:2273–2284. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Prat A, Parker JS, Karginova O, Fan C,
Livasy C, Herschkowitz JI, He X and Perou CM: Phenotypic and
molecular characterization of the claudin-low intrinsic subtype of
breast cancer. Breast Cancer Res. 12:R682010. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Blake RA, Broome MA, Liu X, Wu J, Gishizky
M, Sun L and Courtneidge SA: SU6656, a selective Src family kinase
inhibitor, used to probe growth factor signaling. Mol Cell Biol.
20:9018–9027. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Dittmar T, Husemann A, Schewe Y, Nofer JR,
Niggemann B, Zanker KS and Brandt BH: Induction of cancer cell
migration by epidermal growth factor is initiated by specific
phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR.
FASEB J. 16:1823–1825. 2002.PubMed/NCBI
|
|
32.
|
Hirsch DS, Shen Y and Wu WJ: Growth and
motility inhibition of breast cancer cells by epidermal growth
factor receptor degradation is correlated with inactivation of
Cdc42. Cancer Res. 66:3523–3530. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Playford MP and Schaller MD: The interplay
between Src and integrins in normal and tumor biology. Oncogene.
23:7928–7946. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Ridley AJ, Schwartz MA, Burridge K, Firtel
RA, Ginsberg MH, Borisy G, Parsons JT and Horwitz AR: Cell
migration: integrating signals from front to back. Science.
302:1704–1709. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Azios NG and Dharmawardhane SF:
Resveratrol and estradiol exert disparate effects on cell
migration, call surface actin structures, and focal adhesion
assembly in MDA-MB-231 human breast cancer cells. Neoplasia.
7:128–140. 2005. View Article : Google Scholar
|
|
36.
|
Campbell DH, deFazio A, Sutherland RL and
Daly RJ: Expression and tyrosine phoshorylation of EMS1 in human
breast cancer cell lines. Int J Cancer. 68:485–492. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Ceccarelli S, Cardinali G, Aspite N,
Picardo M, Marchese C, Torrisi MR and Mancini P: Cortactin
involvement in the keratinocyte growth factor and fibroblast growth
factor 10 promotion of migration and cortical actin assembly in
human keratinocytes. Exp Cell Res. 313:1758–1777. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Huang C, Liu J, Haudenschild CC and Zhan
X: The role of tyrosine phosphorylation of cortactin in the
locomotion of endothelial cells. J Biol Chem. 273:25770–25776.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Weed SA, Du Y and Parsons JT:
Translocation of cortactin to the cell periphery is mediated by the
small GTPase Rac1. J Cell Sci. 111:2433–2443. 1998.PubMed/NCBI
|
|
40.
|
Ren G, Helwani FM, Verma S, McLachlan RW,
Weed SA and Yap AS: Cortactin is a functional target of
E-cadherin-activated Src family kinases in MCF7 epithelial
monolayers. J Biol Chem. 284:18913–18922. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Brown MC and Turner CE: Paxillin: adapting
to change. Physiol Rev. 84:1315–1339. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
42.
|
Vincent AM and Feldman EL: Control of cell
survival by IGF signaling pathways. Growth Horm IGF Res.
12:193–197. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
43.
|
Biscardi JS, Tice DA and Parsons SJ:
c-Src, receptor tyrosine kinases, and human cancer. Adv Cancer Res.
76:61–119. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Ravichandran KS: Signaling via Shc family
adapter proteins. Oncogene. 20:6322–30. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45.
|
Bae SN, Arand G, Azzam H, Pavasant P,
Torri J, Frandsen TL and Thompson EW: Molecular and cellular
analysis of basement membrane invasion by human breast cancer cells
in matrigel-based in vitro assays. Breast Cancer Res Treat.
24:241–255. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Jackson JG, Zhang X, Yoneda T and Yee D:
Regulation of breast cancer cell motility by insulin receptor
substrate-2 (IRS-2) in metastatic variants of human breast cancer
cell lines. Oncogene. 20:7318–7325. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
47.
|
Tong GM, Rajah TT and Pento JT: The
differential influence of EGF, IGF-I and TGF-beta on the
invasiveness of human breast cancer cells. In Vitro Cell Dev Biol
Anim. 36:493–494. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
de Blaquiere GE, May FE and Westley BR:
Increased expression of both insulin receptor substrates 1 and 2
confers increased sensitivity to IGF-1 stimulated cell migration.
Endocr Relat Cancer. 16:635–647. 2009.PubMed/NCBI
|
|
49.
|
Lester BR and McCarthy JB: Tumor cell
adhesion to the extracellular matrix and signal transduction
mechanisms implicated in tumor cell motility, invasion and
metastasis. Cancer Metastasis Rev. 11:31–44. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
50.
|
Yamaguchi H, Pixley F and Condeelis J:
Invadopodia and podosomes in tumor invasion. Eur J Cell Biol.
85:213–218. 2005. View Article : Google Scholar
|
|
51.
|
Zigmond SH: Signal transduction and actin
filament organization. Curr Opin Cell Biol. 8:66–73. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
52.
|
Schoenwaelder SM and Burridge K:
Bidirectional signaling between the cytosckeleton and integrins.
Curr Opin Cell Biol. 11:274–286. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
53.
|
DePasquale JA: Rearrangement of the
F-actin cytoskeleton in estradiol-treated MCF7 breast carcinoma
cells. Histochem Cell Biol. 112:341–350. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Bryce NS, Clark ES, Leysath JL, Currie JD,
Webb DJ and Weaver AM: Cortactin promotes cell motility by
enhancing lamellipodial persistence. Curr Biol. 15:1276–1285. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Wang W, Liu Y and Liao K: Tyrosine
phosphorylation of cortactin by the FAK-Src complex at focal
adhesions regulates cell motility. BMC Cell Biol. 13:12–49.
2011.PubMed/NCBI
|
|
56.
|
Mader CC, Oser M, Magalhaes MA,
Bravo-Cordero JJ, Condeelis J, Koleske AJ and Gil-Henn H: An
EGFR-Src-Arg-Cortactin pathway mediates functional maturation of
invadopodia and breast cancer cell invasion. Cancer Res.
71:1730–1741. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Artym VV, Zhang Y, Seillier-Moiseiwitsch
F, Yamada KM and Mueller SC: Dynamic interactions of cortactin and
membrane type 1 matrix metalloproteinase at invadopodia: defining
the stages of invadopodia formation and function. Cancer Res.
66:3034–3043. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58.
|
Small JV and Resch GP: The comings and
goings of actin: coupling protrusion and retraction in cell
motility. Curr Opin Cell Biol. 17:517–523. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
59.
|
Liu X and Feng R: Inhibition of epithelial
to mesenchymal transition in metastatic breast carcinoma cells by
c-Src suppression. Acta Biochim Biophys Sin (Shanghai). 42:496–501.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
60.
|
Helwani FM, Kovacs EM, Paterson AD, Verma
S, Ali RG, Fanning AS, Weed SA and Yap AS: Cortactin is necessary
for E-cadherin-mediated contact formation and actin reorganization.
J Cell Biol. 164:899–910. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61.
|
Zhang K, Wang D and Song J: Cortactin is
involved in tran-forming growth factor-beta1-induced
epithelial-mesenchymal transition in AML-12 cells. Acta Biochim
Biophys Sin (Shanghai). 41:839–845. 2009. View Article : Google Scholar : PubMed/NCBI
|
